Subscribe
shutterstock_664142593_jonathan_weiss
Jonathan Weiss / Shutterstock.com
18 December 2019Big PharmaSaman Javed

Eli Lilly and Eagle Pharma settle antitrust and infringement claims

US-based Eagle Pharmaceuticals has dropped its patent infringement and antitrust claims against Eli Lilly.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Eli Lilly can’t avoid royalties in insulin suit
21 October 2021   Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.
Americas
FDA warns of ‘grave’ knock-on effects from Eagle decision
29 May 2020   The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.
Americas
Fed Circuit affirms generic maker’s win over Eagle
11 May 2020   The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Eli Lilly can’t avoid royalties in insulin suit
21 October 2021   Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.
Americas
FDA warns of ‘grave’ knock-on effects from Eagle decision
29 May 2020   The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.
Americas
Fed Circuit affirms generic maker’s win over Eagle
11 May 2020   The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.

More on this story

Big Pharma
Eli Lilly can’t avoid royalties in insulin suit
21 October 2021   Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.
Americas
FDA warns of ‘grave’ knock-on effects from Eagle decision
29 May 2020   The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.
Americas
Fed Circuit affirms generic maker’s win over Eagle
11 May 2020   The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB